Risk of intracranial haemorrhage with tipranavir

Boehringer Ingelheim has issued a safety warning for its protease inhibitor Aptivus (tipranavir) advising of the risks of intracranial haemorrhage that may be associated with use of the product.

The safety warning was issued following reports of 14 cases of intracranial haemorrhage, including eight fatalities, among 6,840 HIV-infected patients receiving Aptivus in clinical trials.

Although many of the patients had other conditions or were receiving concomitant medication that could have contributed to the intracranial haemorrhage and patients with advanced HIV disease are at an increased risk of suffering such an event, the role of tipranavir cannot be excluded.

Consequently, healthcare professionals are being advised that Aptivus should be used with caution in patients who may be at an increased risk of bleeding from trauma, surgery or other medical conditions, or who are receiving concomitant medication that is known to increase the risk of bleeding.

Further information: Boehringer Ingelheim Ltd, Ellesfield Avenue, Bracknell, Berkshire RG12 8YS. Tel: (01344) 424600.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more